Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director

On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the "Company") of his resignation from the Board of Directors (the "Board"), effective immediately. Dr. Dolsten's resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Election of Director

On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board. Dr. Honig has been designated as a Class III director to serve a term that will expire at the Company's 2022 annual meeting of stockholders. He will serve in accordance with the Company's By-laws until his successor has been duly elected and qualified or until his earlier death, removal or resignation. In connection with his election to the Board, Dr. Honig was appointed to the Board's Commercialization and Portfolio Committee.

There are currently no arrangements or understandings between Dr. Honig and any other person pursuant to which Dr. Honig was elected as a director. There are currently no transactions in which Dr. Honig has an interest requiring disclosure under Item 404(a) of Regulation S-K.

In connection with his election as a non-employee director and pursuant to the Company's Non-employee Director Compensation Policy (the "Policy"), which is filed as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, Dr. Honig will receive an annual cash retainer of $50,000 for service on the Board and $10,000 for service as a non-chair member of the Commercialization and Portfolio Committee, each prorated based on the effective date of his appointment, as well as reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and committees thereof. In addition, in accordance with the Policy, the Board granted Dr. Honig an option to purchase 47,800 shares of the Company's common stock under the Company's 2013 Stock Incentive Plan. The option has an exercise price of $6.72, which is equal to the closing price of the Company's common stock on the date of grant, and will vest with respect to one-third of the shares underlying the option on the first anniversary of the date of grant and with respect to an additional 1/36th of the total number of shares underlying the option at the end of each successive month following the first anniversary of the grant date until the third anniversary of the grant date, subject to Dr. Honig's continued service to the Company on the applicable vesting dates. Dr. Honig will also be entitled to all other applicable compensation described in the Policy. In connection with his election to the Board, the Company will enter into an indemnification agreement with Dr. Honig in substantially the same form as the Company has entered into with each of the Company's existing directors and as previously filed with the Securities and Exchange Commission. The indemnification agreement requires the Company, to the full extent permitted by law, to indemnify Dr. Honig, and advance expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him, in actions or proceedings arising out of his service as a director.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses